Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

5 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    Determination of mutation frequencies in cells treated with chemotherapy drugs following caspase inhibition. TK6 cells were incubated with no inhibitor or 10 μM QVD then treated with the following drug doses: 300 ng/ml TRAIL, 0.7 μM cisplatin, 0.5 μM temozolomide, 3 nM doxorubicin, 0.5 nM SN38 or 0.07 nM vincristine. (a) Caspase activity was assessed by luminescent detection of Caspase-3/-7 Glo reagent after 5 h. After 24- h treatment, (b) clonogenicity assays were performed to determine the proportion of cells maintaining clonogenic competency after treatment, whereas (c) surviving cells were grown in 6TG to select for the emergence of any HPRT mutants. (d) Clonogenicity and (e) HPRT mutation assays were repeated in CASP3/7 DKO lines in the same manner. Error bars represent mean±S.E.M. from at least three independent experiments. Two-sided T-tests were used to calculate P-values.

    Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454. Vincristine sulfate purchased from Selleck.

  • Discrimination of micronuclei induced by EMS and VCR in V79-hCYP2E1-hSULT1A1 cells as CENP-B negative or positive. The cells were treated with EMS (5 mM) or VCR (5 nM) for 6 h, followed by a recovery period of 18 h. They were stained for CENP-B (green) and β-tubulin (red) by the immunofluorescence assays, as described in Section 2.5. DNA was stained with DAPI (blue). The vertical and horizontal arrows indicate CENP-B-negative and CENP-B-positive micronuclei, respectively.

    Chemosphere, 2018, 210:467-475. Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

  • c Quantification of surviving colony numbers from clonogenic assays of D283 Med cells exposed to 10, 20, or 40 μM lomustine with or without 10 nM E2 (n = 6 for each group). d Quantification of colony number from clonogenic assays of D283 Med cells exposed to 5, 10, or 20 nM vincristine with or without 10 nM E2 (n = 8 for each group). All results are expressed as mean ± SEM. Significant differences from the control group were determined by two-way ANOVA followed by Holm-Sidak’s post-test analysis and is indicated above the error bars; * p ≤ .05

    BMC Pharmacol Toxicol, 2017, 18(1):63. Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NGe2VmhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXfqV3MzOC1yLkWg{txO NXH4bpdZOjRiaB?= MlLr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M4CwW|I2PjZ|N{[5
HepG2-HBV1.1 MkPrRZBweHSxc3nzJGF{e2G7 Moj5NE0xNjVizszN M2fVS|I1KGh? Mlv4bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M4LaZlI2PjZ|N{[5
HepG2.2.15 MWLGeY5kfGmxbjDBd5NigQ>? NF[1TpoxNjFizszN MYqyOEBp Mon2dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u M2fxcFI2PjZ|N{[5
HepG2-HBV1.1 MkjNSpVv[3Srb36gRZN{[Xl? M2PteFAvOSEQvF2= NH7FWW4zPCCq MkHFdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NIHrWWQzPTZ4M{e2PS=>
HepG2-HBV1.1 NV;uW|EzTnWwY4Tpc44hSXO|YYm= MmfwNE4yKM7:TR?= Mm\EOFghcA>? M4HHcJBzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>? MX2yOVY3Ozd4OR?=
HepG2-HBV1.1 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLMV4RXOC5zIN88US=> M2fjclEuPSCm M3jsO4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= NVvDNlJvOjV4NkO3Olk>
HepG2-HBV1.1 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVftRnlyOC5zIN88US=> MWCxMVUh\A>? NVLkOmpicW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NIOwOFMzPTZ4M{e2PS=>
HepG2-HBV1.1 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjZXFFzOC5zIN88US=> MUKxNk04OiCq NV30XpUxcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm M33Qb|I2PjZ|N{[5
HepG2-HBV1.1 NYrPVIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3wSoUxNjFizszN NV;Q[GhbOTJvN{KgbC=> MUjpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= Ml;BNlU3PjN5Nkm=
Raji Mn:wSpVv[3Srb36gRZN{[Xl? NI\F[WoxNjYEoN88US=> NW\jUpBkPzJiaB?= M2HqUIFjd2yrc3jld{BifXSxcHjh[5nDqA>? NF;LOYszPTR2NkO3Oy=>
SK-MEL-28  MYHGeY5kfGmxbjDBd5NigQ>? Ml2xN|Ahdk1? NXzhRpVOPiCq MXvpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? NWroTXVnOjV|MUOwNVA>
H157 NGPKNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwMEOgxtEhOC5yNDDtbZUzVQ>? MUKyOVI2PzlzMR?=
Jurkat NHf0Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxMVMhdk1? MnHHOFjDqGh? M{jlNmROW09? MUTk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 MYKyOVE2PjF2Nh?=
CEM NWTZZXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\qV4lNOS1|IH7N M1XKeFQ5yqCq MXXEUXNQ M2\hUIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MnrmNlUyPTZzNE[=
P12 NIf5RnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfxeo0yNTNibl2= M1fySlQ5yqCq M2HVPGROW09? NYjxXZY{\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NFrUfHIzPTF3NkG0Oi=>
KB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP Ml7mNlUxPTh3Mk[=
KBv200 (ABCB1) M1jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DIeGlEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= NHjlRZozPTB3OEWyOi=>
SUDHL6  Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHheWFrOeLCid88US=> M4jJdFQ5Nzd{IHi= MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC|aXfubYZq[2GwdHz5 NGTxSGwzPDl4MU[wOC=>
SUDHL6  M1jLcWZ2dmO2aX;uJGF{e2G7 NGHybZMy6oDLzszN MkLtO|IhcA>? NYfaW5l7cW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= NWfhUnBROjR7NkG2NFQ>
HCT-116 M1XMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzGfIdIUTVyPUWgcm0> MkTKNlQ6Ojd6NUe=
SKNBe2C M{LaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnqPHlKSzVyPUOyMljDuTRwMDDuUS=> M1K1d|I1QTJzOUKw
IGNR91 M2jrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDPbXp{UUN3ME2yOE4{yrFzLkegcm0> M2i5TlI1QTJzOUKw
SKNAS NVPaemlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0e4tKSzVyPUGuOeKyOC5{IH7N M{\jeFI1QTJzOUKw
LAN1 NYi5PYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH1TWM2OD1{LkRCtVAvOiCwTR?= MoHFNlQ6OjF7MkC=
SHSY5Y MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzNbYZKSzVyPUiuNuKyOC54IH7N M1XxS|I1QTJzOUKw
A549-WT NIXpO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTLTWM2OD1zOT60N|chyrFiMD61PVQhKG6P NGfPWJAzPDh3OEiyOy=>
A549-R MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPLXI1{UUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N MnHjNlQ5PTh6Mke=
MCF-7-WT M{Pn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zvOmlEPTB;MUeuO|UzKMLzIECuNlE5KCCwTR?= MXeyOFg2QDh{Nx?=
MCF-7-R MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P6fGlEPTB;NT61N|khyrFiMD6xOFQhKG6P NF[1WIQzPDh3OEiyOy=>
A549-R MoezR5l1d3SxeHnjbZR6KEG|c3H5 NU\nO5N3UUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= Mnm0NlQ5PTh6Mke=
MCF-7-R MWjDfZRwfG:6aXPpeJkhSXO|YYm= MV7JR|UxRTVwNUO5JOKyKDBwMUS0JI5O MnTiNlQ5PTh6Mke=
SW620 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\hTWM2OD15LkiwJOKyKDBwMEigcm0> NWHLcG1vOjR5Mk[3N|k>
SW620/AD300 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HI[WlEPTB;OUC5MlYxKMLzIEiuPVEhdk1? MXmyOFczPjd|OR?=
HEK293/pcDNA3.1 NYXHb2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTwOplGUUN3ME2xMlQ2KMLzIECuNlAhdk1? NWLqclU3OjR5Mk[3N|k>
HEK293/ABCC1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;1fGlEPTB;MUmuNlkhyrFiMj6wPEBvVQ>? MlvQNlQ4OjZ5M{m=
TCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3xNlQhcA>? MoXETWM2OD15MDDuUS=> NGHYNJgzPDdzNkm0OC=>
TCC NXrleWJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHoOFghcA>? MXfJR|UxRTVyIH7N Mli2NlQ4OTZ7NES=
HepG2/ADM MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXuTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? MUOyOFcxPDV3Nh?=
HepG2 NFXRem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojLTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? MnLtNlQ4ODR3NU[=
MCF-7/ADR MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvhTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? Mlv3NlQ4ODR3NU[=
MCF-7 M1;vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj3TWM2OD1yLkCxOVnDuTBwMEC2NkDPxE1? M1voUVI1PzB2NUW2
A-172  NIXFNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHBS3UxNjIEoN88US=> MmHjNlQwPzJiaB?= NEP3OYlqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NH2zW2kzPDV|MEKzOS=>
U-251MG M{nLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNTJUxNjIEoN88US=> NXy1VWdpOjRxN{KgbC=> MnLGbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MW[yOFU{ODJ|NR?=
DLD-1 MmHRSpVv[3Srb36gRZN{[Xl? Mn7vNVAxKG6P MYi0PEBp MVLwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NFq2UIUzPDRyM{S1Ny=>
CCD18Co MYrGeY5kfGmxbjDBd5NigQ>? NV3YTmNYOTByIH7N NV;icpVwPDhiaB?= MWXwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NYD2VJhOOjR2MEO0OVM>
DLD-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWzNE0yODByIH7N NWSw[2c2PDhiaB?= NXXL[o9zcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NV\HS|VrOjR2MEO0OVM>
CCD18Co NHO4S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqdVVMOC1zMECwJI5O NICzPXU1QCCq NV2zVXQ5cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MojZNlQ1ODN2NUO=
HepG2 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrmNlQhcA>? MWnJR|UxRTV{LkZihKnPxE1? M4PHWVI1OzRzNki4
HEK293/pcDNA3.1 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnUS4VKSzVyPUCuNFA1yrFyLkCwNFMh|ryP MWGyOFI5PDd6Mx?=
HEK293/MRP1 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnRTWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? M4PqNlI1Ojh2N{iz
Ramos NH;uclBCeG:ydH;zbZMhSXO|YYm= NVTuU245OuLCid88US=> M{PWVlQ5KGh? NYrVelVNcW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| MnO1NlQzPTZ2OUG=
NCI-H1299/pcDNA3 NVPxNotuS2WubDDWbYFjcWyrdImgRZN{[Xl? NFfsTmgxNTJyIH7N MWm5OkBp MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{\0cFI1OTd5MEGy
H1299/ICAM-3 NWjJcGNrS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn3INE0zOCCwTR?= NGLVeo46PiCq M3\vfolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NI\LWHMzPDF5N{CxNi=>
NCI-H1299/pcDNA3 NXzWc4V7TnWwY4Tpc44hSXO|YYm= NV7VNZVnOS93L{GwM|IxyqCwTR?= NGjkepg6PiCq MX\pcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ M3nVbFI1OTd5MEGy
H1299/ICAM-3 MYPGeY5kfGmxbjDBd5NigQ>? NGX6cpkyNzVxMUCvNlDDqG6P NG[ydYM6PiCq MU\pcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ M3rvXlI1OTd5MEGy
W1 NXfifHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTJTWM2OD1yLkCwN|Ih|ryP NVnx[Y51OjRzNECxO|Y>
W1VR M2fZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfm[GNKSzVyPUCuNFU3KM7:TR?= MnvlNlQyPDBzN{[=
K562 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmxTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP MkXXNlQyOzV7M{e=
K562/ADR MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILlVmJKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= M1Lk[FI1OTN3OUO3
K562 Mo\RRZBweHSxc3nzJGF{e2G7 MknpNE4{KM7:TR?= M4nROVI1KGh? M2PES4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MmTHNlQyOzV7M{e=
K562/ADR NGnkNnpCeG:ydH;zbZMhSXO|YYm= NIjIbpM{KM7:TR?= MlPlNlQhcA>? MYTpcoR2[2W|IHHwc5B1d3Orcx?= Ml6xNlQyOzV7M{e=
A549 NFXQU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjyZoVKSzVyPUCuNVAhyrFiMD6wN{DPxE1? NHm0SVgzOzl5MUC3OS=>
K562 NF7xUoJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFG0fVE{Njd34pETOlDDqG6P Mm\aO|LDqGkEoB?= NHHLd|hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYSyN|g4PzJ{Mx?=
lucena MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGHDNJA{Njd34pETOlDDqG6P Mk\1O|LDqGkEoB?= NYjlU2p2dm9iZX\m[YN1 NIfzXWUzOzh5N{KyNy=>
FEPS NF\BTHhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV2zMlc26oDVNkFCpI5O NVvmVIJGPzMEoHlCpC=> MUDuc{Bm\m[nY4S= MY[yN|g4PzJ{Mx?=
A2780 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwNTDtUS=> NXzicGgyOjN6MkmyNFM>
ACHN NX7aT4ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRDBwMTDtUS=> NHrvWJMzOzh{OUKwNy=>
U-937 NYe2UJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPjTWM2ODx|NDDuUS=> NH;MTXczOzh{OUKwNy=>
Jurkat NHzrVpRCeG:ydH;zbZMhSXO|YYm= NXHl[3BmPcLizsznM41tyqB? NF;n[mozPCCq MVXpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NHjVc2QzOzhzMESwPS=>
Jurkat M{TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[1xsDPxGdxbX|CpC=> MYKyOEBp NH7LWIFienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= MX:yN|gyODRyOR?=
Hep-2 NE\4eHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXnTWM2OD1yLkC0xtExNjBzIN88US=> Mn;zNlM4QDB2MkS=
Hep-2/v NHTKcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\DTmlEPTB;MT64xtExNjJyIN88US=> MYWyN|c5ODR{NB?=
SGC-7901 NH\DTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ofGQxNTFyIN88[{9udA>? Mmq3NlQwPDhxN{KgbC=> NELPXJdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NVz6SY4yOjN5NEO1O|I>
SGC-7901/VCR MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3XnB7OC1zMDFOwIcwdWx? NXXifFRCOjRxNEivO|IhcA>? MkP3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NGnBN4UzOzd2M{W3Ni=>
SGC-7901 NIPTZW9CeG:ydH;zbZMhSXO|YYm= NH3xTldqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M1TOfFI{PzR|NUey
SGC-7901/VCR NXPiO|ZuSXCxcITvd4l{KEG|c3H5 MYnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M3;kU|I{PzR|NUey
KB-3-1 NWn0RVdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fR[mlEPTB;MT62OkDDuSByLkG2NkDPxE1? MW[yN|Y4OzR2NR?=
KB-C2 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[1e2VKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN M1TFNVI{Pjd|NES1
KB-3-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHXTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? NETzWIgzOzZ5M{S0OS=>
KB-V1 M2DkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TCS2lEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP NVrZT2Y4OjN4N{O0OFU>
HEK293/pcDNA3.1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3V5dKSzVyPUK0MlEhyrFiMD6yNFQh|ryP NEXEepQzOzZ5M{S0OS=>
HEK293/ABCB1 NF;NbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\5TWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= NWDmfXdwOjN4N{O0OFU>
A549/EGFP  MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWyXW8xNjBzLUGwNFAh|ryP NV3ScVlLUUN3ME24Ok44KMLzIEK5MlEh|ryP M2XsXFI{PjN2Mkiy
A549/Slug M3n4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PRc|AvODFvMUCwNEDPxE1? NGXxcHhKSzVyPUmuO{DDuSB|LkGg{txO MnnqNlM3OzR{OEK=
JFCR39  M2fUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\6UWJnOSEEtV2= Mni0NlQhcA>? Mk\GSG1UVw>? M2m1c41iemunZHz5JIlv[3KnYYPld{B1cGViboXtZoVzKG:oIFeyM20heGijc3WgZ4VtdHN? NFP1V5ozOzV7OEK3Oi=>
A549 M4PSRmZ2dmO2aX;uJGF{e2G7 NVnD[|duOTByIH7N MlK1NVYhcA>? NGqxc2hFVVOR NFTuXFBt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| NUS4TlFnOjN3OUiyO|Y>
SGC7901 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nRVGlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> MoG4NlM2PjR2OEK=
SGC7901/LV-NC M3TXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHNN4ZKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t MUWyN|U3PDR6Mh?=
SGC7901/LV-SGO1 M1LMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLJTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> NIjxTXIzOzV4NES4Ni=>
SGC7901/VCR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDXTWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> M17h[VI{PTZ2NEiy
SGC7901/VCR-NC M{fOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3tTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> MX[yN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 NX;jRo9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO3OWVDUUN3ME22MlE56oDLwsJihKkyNjB|IN88[{9udA>? NV;Dfm9pOjN3NkS0PFI>
SGC7901/ADR M3fFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojSTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> NI\XdmEzOzV4NES4Ni=>
SGC7901/ADR-NC M{TG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s NHLMV5AzOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 NV[xTZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG1fXdKSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t MVWyN|U3PDR6Mh?=
SH-SY5Y  NFv3VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DFblAvODBzLUGwJO69VQ>? NXL5bW5iOjRiaB?= NUCxfm1EUUN3ME2wMlEyO8LzMD6wNVIh|ryP M3P0[|I{OTJ7ME[1
SH-SY5Y  NWrZWZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlAxOS1zMDFOwG0> NGfG[GI1QCCq MkC4TWM2OD1yLkC3POKyOC5yMEmg{txO MXSyN|EzQTB4NR?=
SH-SY5Y  NV3Wc4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4NnhMOC5yMEGtNVAh|ryP M1znPFczKGh? NWfUcWltUUN3ME2wMlA2OcLzMD6wNFgh|ryP MojJNlMyOjlyNkW=
SH-SY5Y Moe5RZBweHSxc3nzJGF{e2G7 NETvbmsxNjFizszN NHjTUZYxNTJ2IHi= MlzybY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= M2TDeFI{OTJ7ME[1
SH-SY5Y NI[1d2FCeG:ydH;zbZMhSXO|YYm= Mnn5NE4yKM7:TR?= MlPCNE0zPCCq MkHKbY5lfWOnczDtbZRwfGmlIHHydoV{fMLi Mn\yNlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03871257 Not yet recruiting Low Grade Glioma|Neurofibromatosis Type 1|Visual Pathway Glioma National Cancer Institute (NCI) May 3 2019 Phase 3
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID